Summary The Second Meeting of the British Society for Immunology Tumour Immunology Affinity Group (TIAG) took place at King's College (London, UK) on 17-18 June 1997 and brought together over 100 tumour immunologists from the UK and abroad. In contrast to previous meetings the focus of the meeting was on the role of adhesion in immunosurveillance and tumour dissemination. In addition, recent achievements in the areas of chemokines, cytotoxic T-lymphocyte (CTL) and natural killer (NK) cells, co-stimulation, gene and adoptive immunotherapy were also addressed. The purpose of this report is to outline current trends in tumour immunology.
ADHESION AND CHEMOTAXIS
The conference began with an overview of cell adhesion molecules in the interaction of leucocyte and tumour cells with the endothelium (Dr N Hogg, London, UK). Well-known adhesive ligands were described including PSGL-1 (a ligand for all three selectins, especially relevant for neutrophil adhesion), CD44 [as a rolling receptor for haematopoietic (DeGrendele et al, 1996) and potentially non-haematopoietic cells, such as pancreatic carcinoma and melanoma] and a4p1 (adherence receptor for leucocytes and tumour cells) (Figure 1 ). The role of cell adhesion in leucocyte activation ('in/out' signalling) was also highlighted. Furthermore, chemokines, with few exceptions (Szabo et al, 1997) , appear unable to activate adhesion molecules (such as LFA-1) on nonprimed T lymphocytes, as 'naive' T cells do not express corresponding chemokine receptors. However, the adhesion molecules on activated leucocytes can be 'switched on' if chemokine receptors are cross-linked (e.g. the cross-linking of IL-8 receptors by IL-8 bound to extracellular matrix proteins). N Hogg also discussed the ability of the a4,Bl integrin complex to either facilitate (Matsuura et al, 1996) or inhibit (Qian et al, 1994 ) the metastasis of neoplastic cells by decreasing the invasive potential of melanoma and even by inducing apoptosis of lymphoma cells (if expressed in situ). Furthermore, additional studies described the ability of the metalloproteinase MMP2 to form a complex with aVP3 integrin (vitronectin R) (Brooks et al, 1996) and facilitate melanoma cell migration through its ability to digest collagen, unveiling its hidden RGD sequence and thus permitting integrin-mediated adhesion. In another model, the urokinase-type plasminogen activator receptor (uPAR) forms a complex with active integrins, which has the effect of destabilizing integrin adhesion and promoting adhesion and migration on vitronectin, thus potentially enhancing the invasive properties of tumour cells (Wei et al, 1996) .
The adhesion and trafficking mechanisms of lymphocyte transmigration in both normal and adjacent tumour endothelium remain poorly understood. In an elegant in vivo model using a mouse cremaster muscle implanted with a tumour and fluorescent confocal microscopy, murine lymphocytes were examined for their ability to traffic into tumour-bearing tissues (Dr N Brown, Sheffield, UK). Quite unexpectedly, IL-2-activated T cells and lymphocytes from previously immunized but not naive animals appeared to be 'trapped' by endothelium adjacent to tumour. This local arrest/extravasation could be partly blocked by the use of antibodies specific for VLA-4 and VCAM, confirming an involvement of these integrin molecules in the trafficking event rather than a purely mechanical non-specific homing mechanism.
An elegant in vitro model of lymphocyte migration from blood to lymph node (involving transmigration of lymphocytes through high endothelium cells) also demonstrated the role of VLA-4NVCAM-1 in the lymphocyte trafficking process (Dr A Ager, London, UK). Although blocking of LFA-1/ICAM-1 interactions alone did not affect the T-cell transmigration, when combined with block of VLA-4NCAM-1 interactions, lymphocyte movement was almost totally abolished. Freshly isolated CD4+ and CD8+ T cells as well as B lymphocytes but not lymphoma cells (WEHI, Jurkat) behaved similarly in these assays. Interestingly, the inhibition of L-selectin shedding through the use of the zinc-dependent matrix metalloproteinase inhibitor Ro 31-9790 also prevented the lymphocyte migration. Additional studies also revealed the existence of a novel, phorbol ester inducible, metalloproteinase (L-selectin sheddase) responsible for the L-selectin shedding (Preece et al, 1996) . Figure 1 Possible mechanisms of tumour cell extravasation. While the mechanisms by which leucocytes migrate from the vascular space into surrounding tissues are well characterized, much less is known of the extravasation of metastasizing tumour cells. However, studies of various tumour cell lines suggest that they use similar cell-surface molecules to mimic at least some of the leucocyte adhesion mechanisms. Despite such similarities with leucocytes, the complete sequence of events leading to trans-endothelial migration of any one metastasizing cell type will depend on its unique adhesive repertoire, and is yet to be determined. aGiavazzi et al (1993) . bMatsuura et al (1996) . cBrooks et al (1996) . dWei et al (1996) Table 1 Members of the C-X-C, C-C and C chemokine superfamily (Charpin et al, 1997) .
In addition to adhesive interactions, chemokines also play an important role in the trafficking (Taub and Oppenheim, 1994; Taub, 1996) of a variety of immunocompetent cells (Table 1 ; Dr DD Taub, Baltimore, MD, USA). Chemokines are a family of lowmolecular-weight peptides that have from 20% to 70% amino acid homology and are related by a conserved motif containing four cysteine residues. The chemokine superfamily is separated into four distinct families (C-X-C, C-C, C, C-X-X-C) based on their chromosomal localization, primary and secondary structures, and the placement and spacing of conserved cysteine motifs. Each of these chemokines has been shown to induce the directional migration of selected cell types, including granulocytes, monocytes and lymphocytes (Table 2 ). In addition, many tumours can also constitutively secrete or be induced to express these chemotactic molecules. While the biological relevance of tumour-produced chemokines remains obscure, studies have revealed that several chemokines can stimulate tumour cell growth in an autocrine manner (e.g. IL-8 and melanoma). In addition, several C-X-C chemokines have been shown to possess either angiogenic (IL-8) or angiostatic (IP-1O) activities, which appear to modulate tumour growth in vivo. Alternatively, constitutive chemokine production by certain tumour cells has been suggested to break down the local chemokine gradient and, by this means, inactivate chemotaxis of immune cells into various tissues or tumour sites (Dr DD Taub).
In general, it is worth noting that the detection of a chemokine by immunoassay most likely reflects its biological activity as no natural antagonists or neutralizing autoantibodies have yet been clearly identified. Furthermore, it has also been shown that the mere presence of chemokine receptors on the surface of a cell population does not necessarily render these cells responsive to soluble chemokine ligands (e.g. IL-8 and NK cells) (Taub and Oppenheim, 1994; Taub, 1996) . In addition, extensive examination of chemokine subfamily effects on a wide panel of human and murine T-cell clones has demonstrated a differential ability to migrate and adhere to adhesive ligands in response to various chemokines, despite the fact that many of these clones were derived from the same donor under identical conditions. Finally, chemokines appear to not only modulate leucocyte trafficking and adhesion but also contribute to T-cell costimulation and IL-2 production, cytotoxic T-lymphocyte (CTL) degranulation and cytolysis, induce B7 co-stimulatory molecule (Pchemokines) on antigen-presenting cells (Taub et al, 1996a) and, in certain cases, may even direct T-cell responses towards either Th2 (MCP-1) or ThI responses (MIP-ax).
An in vivo correlation between MCP-1 expression and the infiltration of ovarian tumours by CD8 lymphocytes (accompanied by CD45+ cells and monocytes) was reported by RPM Negus (London, UK). Local fluctuations of oxygen tension have been (Scholler et al, 1994) . Furthermore, similar changes have been observed in regressing and non-regressing parts of the same primary melanomas, suggesting the presence of different T-cell repertoires (thor . In an effort to understand why specific parts of the same tumour behave differently, it would be interesting to analyse the in situ cytokine production of primary and metastatic lesions. Surprisingly, the induction of HLA-DR on melanomas by IFN-y has correlated with their escape from CTL surveillance (Kirkin et al, 1996) . A similar adverse effect has been also reported in one clinical trial; however, in another trial, the systemic administration of IFN-y was found to restore lost HLA class I expression (Dr A Knuth, Frankfurt, Germany). In the former case, HLA-DR may play a 'reporter' role of unrelated phenotypical changes in melanoma (e.g. FAS ligand (FAS-L) induction). Notably, the CTL-mediated killing of an immunogenic melanoma could be improved by the antibody-mediated neutralization of FAS-L (Dr J Zeuthen).
A prolonged vaccination with HLA-A2-restricted peptides derived from tumour-associated antigens (Melan A, tyrosinase, gplOO) produced encouraging results in patients with progressive stage 4 melanoma. Seven out of 12 patients whose melanomas were progressing achieved stable disease post vaccination (Table  3 ; Dr A Knuth). All patients developed delayed type hypersensitivity (DTH) and CTL responses to at least one peptide (tyrosinase, Melan A and influenza). Improved DTH responses were observed with the addition of intradermal granulocytemacrophage colony-stimulating factor (GM-CSF) administration. Furthermore, immunohistochemical analysis showed an intensive infiltration of biopsies (CD4+, CD8+, CDla+, HLA DR+) and a THI type immune response (IFNy+, TNFa+, IL-4-, IL-IO-). At the same time progressive disease was associated with a local loss of antigen (Melan A, tyrosinase) and/or HLA class I expression. The use of polyvalent vaccines (to avoid a selection of antigenloss variants) combined with certain cytokines (similar to IFN-y in their ability to up-regulate MHC class I expression) as well as an optimizatioi,.of the dose and route of delivery of these specific therapies has been suggested for future protocols.
M Adams (Cardiff) reported on the successful propagation of dendritic cells (DCs) from peripheral blood of healthy donors and patients by IL-4 and GM-CSF. The DCs obtained could be loaded with peptides (HPV 16 E7, HER-2-Neu) and subsequently generate specific CTLs. Unfortunately, DCs expanded from four patients with cervical cancer did not express CDla, even though they expressed similar levels of MHC class II, CD80 (B7-1) and CD54 (ICAM-1). Interestingly, when patients' DCs were used to generate CTLs in vitro the resulting CTL response was defective compared with that achieved with DCs obtained from normal healthy volunteers. Further studies are required to unravel the basis of this defective response and how it might be corrected. E M-L Evans (Cardiff, UK) identified HPV 16 E7-specific CTLs in peripheral blood (four out of five), draining lymph nodes (two out of three) and tumours (one out of three) of cervical cancer patients but not healthy donors. Notably, in all patients tested, the frequency of HPV-specific CTLs was higher in lymph nodes and tumour tissue compared with peripheral blood. J Saba (Sheffield, UK) showed that it is possible to generate CTLs to the HLA-A2-restricted peptides for the melanoma antigens (Melan A, tyrosinase and gplOO) from the peripheral blood of ocular melanoma patients using a bulk culture method that uses a maximum of 60 ml of blood. CTL were generated to all peptides in a donor-dependent fashion and, if a response to tyrosinase was generated, these CTLs were always the most potent cytolytic cells compared with those generated to other antigens.
LG Durrant (Nottingham, UK) reported on studies mapping the helper T-cell epitope within the 105D7 vaccine, an anti-idiotype antibody that mimics the 79Tgp72 antigen, which is overexpressed on colon carcinomas. The corresponding CDRH3 peptide (HLA DR 1, -3 and -7 binding motifs) stimulated T-cell proliferation from naive donors (eight out of eight of permissive haplotype) and could prime them to respond to both 105AD7 or 791Tgp72 positive cells, although the response to the whole Ag (105AD7) was much stronger. In addition, a DNA vaccine incorporating heavy-and light-chain variables of 105AD7 antibody has been produced and shown in preliminary experiments to induce antibody production in a mouse model (Dr V Potter, Nottingham, UK).
GENE AND ADOPTIVE IMMUNOTHERAPY
Cancer gene therapy is intended to improve host immunosurveillance pathways that a tumour may evade through a number of mechanisms. These include decreased immunogenicity (e.g. down-modulation of HLA class I molecule or antigen expression); suppression of the immune system (e.g. up-regulating FASL on tumour and FAS molecules on effector cells); the loss of the TCR zeta chain or DNA binding molecules in T cells obtained from tumour-bearing hosts; and the stimulation of tumour growth and increased angiogenesis (Dr R Vile, London, UK). A fine equilibrium between tumour growth and suppression can be shifted (we all hope) by improving/restoring a number of links in the chains of the immune response (Chong and Vile, 1996) . The successes initially achieved with transfer of IL-2, IL-4 or, later, B7 genes could be explained by bypassing 'the helper arm' and directly activating CD8 and possibly NK cell responses. In contrast, recent success with GM-CSF gene transfer to tumour cells is probably a result of the recruitment and activation of antigen-presenting cells. Several of the approaches tested to date have yielded tumour rejections and, on some occasions, systemic and, most importantly, long-lasting immunity . While there is a worryingly long list of successes achieved using many cytokine or costimulatory genes (Forni and Foa, 1996) , this does not mean that any cytokine transfection can cure cancer but rather reflects the situation that, for any given tumour (model), a particular co-stimulatory combination can be found (or adjusted). However, this does not necessarily echo the situation in patients. Perhaps it is time to stop and think about the mechanisms involved in the generation of an anti-tumour response rather than plunge straight into clinical trials. Gene therapy offers a number of approaches to fighting various tumours. We can attempt to convert tumour cells to antigenpresenting cells by making them more immunogenic (B7 co-stimulation); restore lost MHC molecules; transfect with cytokines capable of a direct stimulation of lymphocytes (IL-2) or even enhance tumour antigen release and its subsequent up-take by professional antigen-presenting cells (presuming that antigenspecific T cells are still in the circulation or can be generated from naive precursors). The last approach also conforms with a recently suggested 'Danger Model' (Ridge et al, 1996) theory according to which induced necrosis may attract antigen-presenting cells (macrophages, dendritic cells), increase their up-take and the subsequent delivery of antigen in an appropriate fashion to T lymphocytes. The recruitment of antigen-presenting cells can be further potentiated by the local production of GM-CSF or IL-12. Based on this rationale and supporting data obtained from animal models, this group hopes to progress to clinical trial in patients with melanoma using retrovirus incorporating the HSV-TK and GM-CSF genes and a tumour-specific promoter/enhancer (e.g. tyrosinase).
A successful effect (50% complete remission) of locally delivered co-stimulatory IL-12 on the growth of otherwise fatal mesothelioma appeared to correlate with the infiltration of tumour with CD4+ and CD8+ lymphocytes (Dr RA Lake, Australia). However, it remains to be established whether there is a connection between IL-12 secretion and the induction of heat shock proteins, as the latter also had a beneficial effect in this tumour (Alexandroff and Dalgleish, 1997) . Furthermore, a phase I clinical trial was conducted in patients with mesothelioma using a replication-defective Vaccinia virus containing cDNA for IL-2 (Dr RA Lake). This trial demonstrated that intralesional administration of the viral construct is safe and non-toxic and results in intratumoral expression of IL-2 for up to 1 week.
AL Barnard (London, UK) reported on the development of a semisyngeneic melanoma vaccine that may be convenient for clinical use. Also, possible difficulties in the expansion of tumour from a cancer patient or finding a completely HLA-matched tumour and encouraging results recently reported about the use of allogeneic melanoma vaccines should be kept in mind when pondering a potential vaccine (Knight et al, 1996) (Mackey et al, 1997) . FAS and FAS-L coexpression was also observed on normal breast epithelial cells, while many breast carcinoma cells appear to lose FAS but continued to express FAS-L (Dr CB Ragnarsson, Reykjavik, Iceland). Overall, the expression of FAS-L has been reported on a number of neoplasms constitutively or after chemotherapy and has been suggested to play an important role in evasion of immunosurveillance (Strand et al, 1997; Walker et al, 1997) .
Because of a high rate of relapse and an acquired resistance to chemo-and radiotherapy, bone marrow transplantation (BMT) remains a therapy of choice for a number of haematological malignancies, including chronic and acute myeloid leukaemia (CML, AML), myelodysplastic, syndrome, etc. Although allogeneic BMT has been shown to have adverse effects (e.g. liver and FAS-Lmediated skin damage), in studies on a large number of patients in Europe and North America, these transplants have been shown to have a lower relapse rate compared with syngeneic BMT. While the precise mechanism of this advantage is not totally clear, the immune response of donor T lymphocytes against residual malignant cells is believed to play an important role in these transplants (Dr E Fuchs, USA). These results have been confirmed, on the one hand, by an inverse correlation between graft vs host (GvH) disease and relapse rate and, on the other hand, by an increased relapse after T-cell purging of donor BMT (up to fivefold in CMLs). Similarly, positive effects have been observed in an animal BMT model. CML cells are notorious for their resistance to both chemotherapy and radiotherapy as a result of the induction of the p2. I0 fusion protein (a product of bcr-abl) and a frequent p53 mutation. However, it appears that, while a pre-B cell line may acquire resistance to chemo-and/or radiotherapy after transfection with p2.10 fusion protein, it still remained sensitive to CTL-mediated lysis. Moreover, thymocytes derived from p53-deficient mice remain readily susceptible to both Fas-and CTL-mediated apoptosis, but are no longer sensitive to radio-and chemotherapy-induced apoptosis. These findings give clear incentives for an immunological approach towards improving allogeneic BMT. Indeed, the infusion of donor T cells to CML patients during blast crisis induced a long-lasting remission (2-5 years) in 62% of the patients. Additional experiments have demonstrated that, in the CML model, purified B cells provided a 'survival' (possibly bclXl associated) rather than a 'proliferative' co-stimulatory signal to T lymphocytes. However, this effect can be reversed using spleen cells, containing dendritic cells. Based on these data, a clinical adoptive immunotherapy trial involving co-transfusion of donor T cells and recipient dendritic cells has been envisaged. The recently reported fusion of dendritic and tumour cells (Gong et al, 1997) 
CONCLUSIONS
This short meeting has highlighted some important new developments in areas related to tumour biology as well as pointing to new directions for the future. Progress has been made in the characterization of some of the molecules involved in cell attachment and migration (of both immune cells and tumour cells), yet further work is required to fully elucidate the mechanisms involved, together with the role of cytokines and chemokines in these processes. NK cells and CTLs are also involved in tumour cell destruction but the recognition and cytolytic mechanisms mediating these responses are unclear. Nevertheless, tumour antigen-based vaccines, in the form of peptides, have shown promising results with future studies being planned incorporating different combinations of peptides or whole antigen molecules in combination with cytokines or immunological adjuvants. Clearly, while advances have been made in understanding the factors involved in leucocyte trafficking and in gene and immunotherapy of cancer, efforts are still needed in all these areas and, until we have a more thorough understanding of all the processes involved in these arenas, no appropriate and effective prevention and treatment of cancer will be available.
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